

A cholinergic medial septum input to medial habenula mediates generalization formation and extinction of visual aversion

Rong-Hao Mu

China Pharmaceutical University

Xiao-Meng Han

China Pharmaceutical University

Hao Wang

China Pharmaceutical University

Su-Su Tang

China Pharmaceutical University

Yan Long

China Pharmaceutical University

Dan-Hua Yuan

China Pharmaceutical University

Hao Hong (✉ honghao@cpu.edu.cn)

China Pharmaceutical University

Article

Keywords: Affective Disorders, Aversion, Cholinergic Circuits, Glutamatergic Neurons

Posted Date: January 8th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-127062/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **A cholinergic medial septum input to medial habenula mediates generalization formation and**
2 **extinction of visual aversion**

3 Ronghao Mu, Xiaomeng Han, Hao Wang, Susu Tang, Yan Long, Danhua Yuan, Hao Hong*

4 Department of Pharmacology, Key Laboratory of Neuropsychiatric Diseases, China Pharmaceutical
5 University, Nanjing 211198, China

6
7 *Address correspondence to:

8 Hao Hong, Prof.

9 Department of Pharmacology, China Pharmaceutical University, Nanjing 211198, China

10 E-mail: honghao@cpu.edu.cn; Tel: +86-25-86185328

24 **Abstract**

25 Generalization formation and extinction of aversion are associated with affective disorders, but little
26 is known about underlying mechanisms. Here, we established a novel procedure for induction of visual
27 aversion by dynamic stripe images on digital screens in mice. We found that decreased activity of
28 medial septum (MS) cholinergic neurons led to generalization aversion loss, but didn't affect its
29 extinction. We identified a new projection from MS cholinergic neurons to medial habenula (MHb),
30 and found that inhibiting MS→MHb cholinergic circuit disrupted generalization formation, while
31 activating this circuit damaged extinction. The further studies showed that blockade of M1 mAChRs
32 rather than $\alpha 4\beta 2$ and $\alpha 7$ nAChRs on downstream glutamatergic neurons that corelease glutamate and
33 acetylcholine blunted generalization enhancement and extinction deficit caused by activation of
34 MS→MHb circuits. These findings reveal that MS→MHb cholinergic circuit modulates generalization
35 formation and extinction of aversion, providing new insights on affective disorders such as PTSD and
36 anxiety disorders.

37

38

39

40

41

42

43

44

45

46

47 **Introduction**

48 When we are exposed to an aversive situation, which may be life threatening, fear or avoidance is the
49 normal adaptive response, indispensable to prevent harmful situations¹. Acquisition and storage of
50 aversive memories is one of the basic principles of central nervous systems (CNS)². In the absence of
51 reinforcement, the resulting behavioural response will gradually diminish to be finally extinct.
52 Extinction of aversive memories is thought to be an active mnemonic process³. Generalization is often
53 described as an inability to discriminate different stimuli⁴. Overgeneralization or extinction deficit may
54 lead to inadequate physiological and behavioral responses that affect daily life⁵. Facilitating the
55 extinction of aversive memory and/or attenuating its generalization could have therapeutic implication
56 in the treatment of some diseases such as post-traumatic stress disorder (PTSD), anxiety disorders, and
57 etc^{6, 7}.

58 Great progress has been made in studies using a form of aversive associative learning termed fear
59 conditioning. It has been demonstrated that fear learning is engaged through multiple, parallel aversive
60 signaling pathways to hippocampus and amygdala^{8, 9, 10}. Some studies indicate that aversive taste
61 memories are established and sustained by parabrachial nucleus calcitonin-gene-related peptide
62 neurons¹¹, and the memory of conditioned taste aversion may be regulated by PI3K in the insular
63 cortex¹². However, there are few reports on visual aversion memory. It is well known that cholinergic
64 neurons are involved in various memories^{13, 14, 15, 16}. Most of the cholinergic projections to cerebral
65 cortex, hippocampus, and amygdala with established roles in memory, fear and anxiety, originate from
66 the basal forebrain, a collection of heterogeneous structures that includes the medial septum (MS)^{17, 18}.
67 Previous studies have shown that cholinergic neurons in the MS maintain anxiety-like behaviors
68 induced by chronic inflammatory pain¹⁹ and inhibiting these neurons with DREADD (designer
69 receptors exclusively activated by designer drugs) alleviates anxiety-like behaviors in mice²⁰.

70 Moreover, disruption of the MS and diagonal bands of Broca cholinergic projections to the ventral
71 hippocampus damages auditory fear memory²¹. The medial habenula (MHb) is a brain center known
72 to regulate negative states^{22, 23, 24}. Previous studies have shown that mu opioid receptors in the MHb
73 contribute to naloxone aversion²⁵, and endocannabinoid control of MHb cholinergic neurotransmission
74 exerts a critical role in the expression of aversive memories²⁶. We are curious whether or how the
75 neurons in MS and MHb modulate visual aversion memory. To address these questions, we established
76 a novel procedure for induction of visual aversion by a dynamic stripe image on digital screens in mice
77 and used apoptotic, optogenetic, chemogenetic and whole-cell patch-recording approaches to
78 investigate the roles of neurons in these two regions in generalization formation and extinction of
79 visual aversion.

80 **Results**

81 **MS provides strong cholinergic projections to the MHb**

82 MS, an important part of basal forebrain cholinergic system, is the major source of cholinergic (as well
83 as non-cholinergic) projections to cingulate cortex, entorhinal cortex and hippocampus²⁷. To track MS
84 novel cholinergic projections, we stereotaxically injected AAV-chat-cre-EGFP vector into the MS (Fig.
85 1a, b). Staining with anti-choline acetyltransferase (ChAT) revealed that $96.3 \pm 0.7\%$ of EGFP-labeled
86 cells were ChAT⁺ neurons, and $92.5 \pm 1.2\%$ of ChAT-stained neurons were EGFP-labeled cells (Fig.
87 1c, d). The cholinergic neurons were also identified by their response to intracellular current injection
88 during whole-cell patch-clamp recordings (Fig. 1e, f). Injection of a negative current pulse produced
89 an initial hyperpolarization followed by a cation conductance I_h -dependent sag in the membrane
90 potential while depolarizing current induced regular spiking and resulted in a long-lasting
91 afterhyperpolarization after cessation of current injection (Fig. 1f). Additionally, in the absence of
92 applied current, spontaneous spiking was observed in this particular neuron. Using virus tracing, dense

93 networks of MS cholinergic projections were observed in the whole MHb (Fig. 1g). These data reveal
94 that MS provides strong cholinergic projections to the MHb in addition to the projections reported
95 previously.

96 **MS cholinergic neuron supports rapid generalization formation and extinction of visual aversion**

97 Visual aversive images are often used in aversive learning which modulates perceptual thresholds on
98 overgeneralization²⁸. To determine whether an image was aversive in mice, we firstly employed real-
99 time place preference (RTPP) caused by vision. In brief, mice were allowed to freely explore a two-
100 chamber apparatus in which each chamber contained four digital screens that displayed one of three
101 images: a blank image, a static stripe image, or the same stripe image that was moving (named as
102 dynamic stripe image), respectively. We found that mice spent significantly less time in the chamber
103 displaying the dynamic stripe image relative to those displaying either the static stripe or blank images,
104 suggesting dynamic stripe images are aversive images. The time exploring the chamber with static
105 stripe images was the same as one with the blank, showing the static images are neutral images (Fig.
106 2a-c and Supplementary Fig. 1). We also submitted those mice to open field test (OFT) and elevated
107 plus-maze (EPM) (Supplementary Fig. 2a). The data showed that mice exposed to the dynamic image
108 exhibited significant reductions in exploration time of center part in OFT and open arms in EPM while
109 no obvious change in freezing time (Supplementary Fig. 2b-e), suggesting that visual stimulations of
110 dynamic images lead to generalized anxiety in mice.

111 Similar with fear, aversion is involved in generalization and extinction^{29, 30, 31}. To explore
112 generalization formation and extinction processes in visual aversion, we designed a task using the
113 highly similar dynamic and static stripe images referring to previous studies^{32, 33, 34, 35} (Fig. 2d). In brief,
114 after two habituation phases of the apparatus, mice were aversively stimulated for 10 min using the
115 dynamic stripe image, and after 1 h, aversion generalization formation was examined using the

116 corresponding static stripe image in one chamber of the apparatus. After a 4 h-delay, we performed an
117 aversion generalization extinction test with the same approach. During habituation phase 1 and 2, mice
118 did not exhibit any differences in the time spent exploring chambers, suggesting that there was no side
119 preference (phase 1) and the static image served as a neutral stimulus (phase 2). After exposure to
120 dynamic images in training phase, mice spent only $34.8 \pm 1.5\%$ of the whole time in the chamber with
121 static stripe images in test phase 1 (Fig. 2e), suggesting that the static image, which was a visual neutral
122 image before, now elicited a significant aversion avoidance response in mice, indicating an aversion
123 generalization formation. After a 4 h-delay, $48.7 \pm 1.0\%$ of the whole time spent by mice in the stripe
124 image chamber showed that mice no longer exhibited aversion for the static image during test phase 2
125 (Fig. 2f), revealing a generalization extinction of visual aversion. However, if mice were tested without
126 dynamic image stimulations in training phase, the static image could not cause generalized aversion
127 behaviors during test phases (Fig. 2g-i). Moreover, we also used a new two-chamber apparatus with a
128 white floor in test phases, and found this modified context did not affect aversion generalization
129 processes (Supplementary Fig. 3). Altogether, these data reveal that there are rapid generalization
130 formation and extinction of visual aversion for the dynamic stripe image.

131 Using c-Fos as a proxy for neuronal activity, we found much higher c-Fos expression in MS
132 cholinergic neurons in aversion generalization formation phase (test phase 1) than both in the
133 extinction phase (test phase 2) and the test phases without aversive stimulations of dynamic images
134 (Fig. 2j, k). We also measured the Ca^{2+} signals of MS cholinergic neurons with fiber photometry in
135 freely moving mice after stereotaxic virus injection of AAV-chat-cre and the cre-dependent AAV-
136 $\text{Efl}\alpha\text{-DIO-GCaMP6m}$ into the MS (Fig. 2l-n). Real-time recording of GCaMP fluorescence signals of
137 MS cholinergic neurons revealed a rapid increase in Ca^{2+} signal when the moving mouse first entered
138 the chamber containing static stripe images during the generalization formation phase (test phase 1;

139 Fig. 3o, left), and Ca^{2+} signals did not significantly change upon entry into the chamber containing
140 static images during the generalization extinction phase (test phase 2; Fig. 2o, right). In addition, the
141 mice unexposed to dynamic images in training phase had a mild increase in fluorescence signal in test
142 phase 1 (Fig. 2p, left) while no change in test phase 2 (Fig. 2p, right). Altogether, these data suggest
143 that MS cholinergic neurons might be involved in generalization formation and extinction of visual
144 aversion.

145 **MS cholinergic neuron activity is necessary for generalization formation and extinction of visual** 146 **aversion**

147 To test whether MS is necessary for generalization formation and extinction, we manipulated MS
148 cholinergic neurons with apoptosis, chemogenetic, and optogenetic approaches. Firstly, after
149 stereotaxic virus injection of AAV-chat-cre-EGFP into the MS, we promoted MS apoptosis with a cre-
150 dependent AAV-CAG-DIO-taCaspase3 (Fig. 3a). The apoptotic approach resulted in a 72% reduction
151 of EGFP-labeled cholinergic neurons in the MS in taCaspase3-expressing mice (Fig. 3b, c). In aversion
152 generalization task, taCaspase3-expressing mice had no aversion avoidance response to the stripe
153 image chamber in the generalization formation phase compared with the control mice (Fig. 3d, e),
154 suggesting that the taCaspase3-expressing mice failed to form a generalized aversion to the static stripe
155 image. To explore whether chemogenetic and optogenetic inhibitions of MS cholinergic neurons
156 disrupt formation of aversion generalization, cre-dependent AAV-Ef1 α -DIO-hM4D(Gi)-mCherry
157 (Supplementary Fig. 4a) or AAV-Ef1 α -DIO-NpHR-mCherry (Fig. 3g) was injected into the MS,
158 respectively. $92.6 \pm 1.3\%$ of EGFP-labeled MS cholinergic neurons expressed hM4D(Gi)-mCherry for
159 chemogenetic inhibition (Supplementary Fig. 5a, b), while $89.8 \pm 1.6\%$ of EGFP-labeled MS
160 cholinergic neurons expressed NpHR-mCherry for optogenetic inhibition (Supplementary Fig. 5c, d).
161 Acute MS slices containing NpHR-mCherry-expressing were prepared, and brief yellow-light (589

162 nm) photostimulation elicited obvious decreases in spontaneous firing on the neurons. (Fig. 3h). As
163 observed with the apoptotic approach, clozapine N-oxide (CNO)-induced chemogenetic inhibition or
164 yellow-light-induced optogenetic inhibition during test phase 1 (Fig. 3f) led to similar exploration in
165 two chambers (Fig. 3i, j and Supplementary Fig. 4b, c). These data revealed that apoptosis,
166 chemogenetic and optogenetic inhibitions of MS cholinergic neurons disrupted generalization
167 formation of visual aversion.

168 To activate MS cholinergic neurons, cre-dependent AAV-Efl α -DIO-hM3D(Gq)-mCherry (Fig.
169 3k) or AAV-Efl α -DIO-ChR2-mCherry (Supplementary Fig. 4e) was injected into the MS, respectively.
170 We found $88.2 \pm 1.6\%$ of EGFP-labeled MS cholinergic neurons expressed hM3D(Gq)-mCherry
171 (Supplementary Fig. 5e, f), $91.5 \pm 2.1\%$ of EGFP-labeled MS cholinergic neurons expressed ChR2-
172 mCherry (Supplementary Fig. 5g, h), and $95.6 \pm 1.1\%$ of EGFP-labeled MS cholinergic neurons
173 expressed mCherry alone (Supplementary Fig. 5i, j). Moreover, increased spontaneous firing of
174 hM3D(Gq)-mCherry-expressing neurons after CNO application to MS slices was also observed (Fig.
175 3l). In aversion generalization task, mice were intraperitoneally injected CNO (2.5 mg/kg) to activate
176 MS cholinergic neurons after generalization formation phase. The data of test phase 2 showed that the
177 chemogenetic activation of MS cholinergic neurons resulted in a significant aversion response to the
178 stripe image chamber in hM3D(Gq)-expressing mice (Fig. 3m, n). Similar results were obtained in
179 optogenetic manipulation (Supplementary Fig. 4d, f, g). These data revealed that continuous
180 activations of MS cholinergic neurons disrupted generalization extinction of visual aversion.

181 In addition, to further evaluate whether apoptosis or chemogenetic inhibition/activation of MS
182 cholinergic neurons lead to gross behavioural abnormality in mice, we conducted OFT, EPM-test, grip
183 strength test (GST), and novel object recognition test (NORT). The results showed that manipulations
184 of MS cholinergic neurons did not change gross behaviors (Supplementary Fig. 6).

185 **MS→MHb cholinergic circuit drives generalization formation and extinction of visual aversion**

186 To dissect the role of the MS→MHb cholinergic circuit in visual aversion generalization, we specially
187 inhibited or activated this circuit with chemogenetic or optogenetic manipulations. For inhibition of
188 the MS→MHb circuit, AAV2/9-chat-cre-EGFP vector was injected into the MS, whereas cre-
189 dependent, monosynaptic retrograde tracing virus AAV2/Retro-Efl α -DIO-hM4D(Gi)-mCherry or
190 AAV2/Retro-Efl α -DIO-NpHR-mCherry was bilaterally injected into the MHb, respectively (Fig. 4a,
191 b and Supplementary Fig. 7a, b). After three weeks, aversion generalization tasks were submitted to
192 the treated or control mice. Both wild-type and hM4D(Gi)-expressing mice were injected with CNO
193 (2.5 mg/kg) intraperitoneally 30 min before generalization formation test. Additionally, the cannulas
194 were bilaterally implanted in the MHb of wild-type and NpHR-expressing mice one week before tasks,
195 and yellow-light photoinhibition was delivered during generalization formation test. The data showed
196 that the hM4D(Gi)- or NpHR-expressing mice had no aversion avoidance response to the stripe image
197 chamber in the aversion generalization formation phase (Fig. 4c, d and Supplementary Fig. 7c, d),
198 indicating that inhibition of the MS→MHb cholinergic circuit disrupted generalization formation of
199 visual aversion.

200 For activation of MS→MHb circuits, AAV2/9-chat-cre-EGFP vector was injected into the MS,
201 whereas cre-dependent, monosynaptic retrograde tracing virus AAV2/Retro-Efl α -DIO-hM3D(Gq)-
202 mCherry (Supplementary Fig. 7e) or AAV2/Retro-Efl α -DIO-ChR2-mCherry (Fig. 4f) was bilaterally
203 injected into the MHb, respectively. After 3-week virus expressions (Fig. 4g and Supplementary Fig.
204 7f), CNO intraperitoneal injection after generalization formation phase or blue-light photostimulation
205 during generalization and extinction phases was performed to activate this circuit (Fig. 4e). We found
206 that continuous activations of the MS→MHb cholinergic circuit disrupted aversion generalization
207 extinction (Fig. 4h, i and Supplementary Fig. 7g, h). Moreover, we also showed that chemogenetic

208 manipulations of the MS→MHb circuit showed no significant alterations in behaviors in Morris water
209 maze (MWM) and Y-maze tests (Supplementary Fig. 8), suggesting the MS→MHb cholinergic circuit
210 mainly regulates visual aversion generalization rather than spatial working memory. Figure 1 have
211 showed that hippocampus CA3, as a key memory center in brain, received cholinergic projections from
212 the MS. To explore whether the MS→CA3 cholinergic circuit is involved in visual aversion
213 generalization, we inhibited this circuit with optogenetic approach. The results showed that inhibition
214 of MS→CA3 projections did not disrupt movement, object recognition and visual aversion
215 generalization in mice (Supplementary Fig. 9). Altogether, the data reveal that MS→MHb cholinergic
216 circuit drives generalization formation and extinction of visual aversion.

217 **M1 mAChRs mediate regulatory effects of the MS→MHb circuit on visual aversion**
218 **generalization**

219 The most commonly expressed mAChRs in the CNS are M1, M2 and M4 receptors³⁶ and the most
220 common nAChR subtypes in the brain are $\alpha 4\beta 2$ and $\alpha 7$ receptors³⁷. Because MHb contains M1, $\alpha 4$,
221 $\alpha 7$ and $\beta 2$ polypeptides (Supplementary Fig. 10a), it is likely that M1, $\alpha 4\beta 2$ and $\alpha 7$ AChRs mediate
222 regulatory effects of the MS→MHb circuit on visual aversion generalization. We bilaterally injected
223 $\alpha 4\beta 2$ and $\alpha 7$ AChRs antagonist benzethonium chloride (2 $\mu\text{g}/0.1 \mu\text{l}/\text{side}$) and M1 mAChRs antagonist
224 pirenzepine dihydrochloride (1.5 $\mu\text{g}/0.1 \mu\text{l}/\text{side}$) into the MHb, respectively. The data showed that
225 inhibition of $\alpha 4\beta 2$ and $\alpha 7$ nAChRs in the MHb did not influence aversion generalization formation
226 and extinction, whereas inhibition of M1 mAChRs disrupted generalization formation (Supplementary
227 Fig. 10b-d), suggesting M1 mAChRs rather than $\alpha 4\beta 2$ and $\alpha 7$ nAChRs mediate regulatory effects of
228 MHb neurons on generalization process of visual aversion.

229 Because MHb acetylcholine signaling transmission is instrumental for the MS→MHb circuit. To
230 further confirm role of acetylcholine signals, after virus AAV2/9-chat-cre-EGFP and cre-dependent

231 AAV2/Retro-Efl α -DIO-hM3D(Gq)-mCherry expressions, we combined targeted expression of
232 hM3Dq in the circuit with direct bilateral microinjections of CNO (3.0 μ M/0.1 μ l/side) or a mixture of
233 pirenzepine (1.5 μ g/0.1 μ l/side) into the MHb (Fig. 5a, b). The results showed that chemogenetic
234 activation of MS \rightarrow MHb cholinergic circuits significantly enhanced aversion generalization formation,
235 whereas blockade of MHb M1 mAChRs attenuated this effect (Fig. 5c, d). These data show that M1
236 mAChRs mediate regulatory effects of the MS \rightarrow MHb cholinergic circuit on generalization of visual
237 aversion.

238 **MHb glutamatergic/cholinergic neurons participate in generalization formation and extinction** 239 **of visual aversion**

240 MHb is mainly composed of glutamatergic neurons which can project to the interpeduncular nucleus
241 (IPN) and other regions³⁸. To explore whether MHb glutamatergic neurons participate in visual
242 aversion generalization, we injected AAV2/9-CaMKII α -cre and an acetylcholine optical sensor virus
243 AAV2/9-Efl α -DIO-ACh2.0 into the MHb³⁹. After three weeks, acetylcholine fluorescence signals in
244 MHb glutamatergic neurons were recorded using a fiber photometry in freely moving mice submitted
245 to aversion generalization task (Fig. 5e, f). The results showed an acute increase in acetylcholine
246 signals upon entering the static stripe image chamber during generalization formation phase of visual
247 aversion, but acetylcholine signals did not significantly change during the generalization extinction
248 phase (Fig. 5g), suggesting that MHb glutamatergic neurons might be involved in visual aversion
249 generalization and receive cholinergic inputs from the MS. Next, we chemogenetically activated
250 MS \rightarrow MHb cholinergic circuits and inhibited MHb glutamatergic neurons together by the bilateral
251 injections of AAV2/Retro-Efl α -DIO-hM3D(Gq) and AAV2/9-CaMKII α -hM4D(Gi) into the MHb
252 after the expression of AAV2/9-chat-cre in the MS. CNO (3.0 μ M/0.1 μ l/side) was bilaterally injected
253 into the MHb 30 min prior to the behavioral test (Fig. 6a, b). The results showed that inhibition of

254 MHb glutamatergic neurons blunted enhancement of aversion generalization formation caused by
255 chemogenetic activation of MS→MHb cholinergic circuits (Fig. 6c, d).

256 Previous study has reported that some MHb neurons could corelease glutamate and acetylcholine
257 (name as glutamatergic/cholinergic neurons)⁴⁰. After staining MHb slices with anti-CaMKII α and
258 anti-ChAT, we showed that $38.4 \pm 2.7\%$ of CaMKII α^+ neurons co-expressed ChAT, and $97.8 \pm 0.8\%$
259 of ChAT $^+$ neurons co-expressed CaMKII α (Fig. 6e). To confirm the roles of MHb
260 glutamatergic/cholinergic neurons in visual aversion generalization, we chemogenetically inhibited
261 MS→MHb cholinergic circuits and activated MHb CaMKII α^+ ChAT $^+$ neurons by bilateral injections
262 of AAV2/9-chat-cre and AAV2/9-Ef1 α -DIO-hM3D(Gq) into the MHb after expressions of AAV2/9-
263 chat-cre and AAV2/9-Ef1 α -DIO-hM4D(Gi) in the MS. CNO (3.0 μ M/0.1 μ l/side) was bilaterally
264 injected into the MHb 30min prior to the behavioral test (Fig. 6f, g). The results showed that activation
265 of MHb CaMKII α^+ ChAT $^+$ neurons protected against aversion generalization deficit caused by
266 chemogenetic inhibition of MS→MHb cholinergic circuits (Fig. 6h, i). Moreover, there was a
267 tendency to disrupt generalization extinction with this activation approach ($P = 0.059$). These data
268 show that MHb glutamatergic/cholinergic neurons participate in generalization of visual aversion
269 regulated by MS→MHb cholinergic circuits.

270 To explore underlying mechanisms of MS→MHb cholinergic circuits mediating visual aversion
271 generalization, after labeling MHb neurons with AAV2/9-CaMKII α -mCherry and AAV2/9-chat-
272 EGFP vectors, we optogenetically activated the MS→MHb circuit by injections of AAV2/9-chat-cre
273 and AAV2/9-Ef1 α -DIO-ChR2-mCherry into the MS, and tested the excitatory postsynaptic currents
274 (EPSCs) of MHb neurons with whole-cell recording (Fig. 7a, b). The results showed that optogenetic
275 activation of MS→MHb cholinergic circuits significantly enhanced the frequency and amplitude of
276 EPSCs of MHb CaMKII α^+ ChAT $^+$ neurons and didn't do in the present of M1 mAChRs antagonist

277 pirenzepine (Fig. 7c-e). However, the EPSCs of MHb glutamatergic neurons labelled with CaMKII α
278 alone (MHb CaMKII α^+ ChAT $^-$ neurons) did not significantly change under activation of MS \rightarrow MHb
279 circuits (Fig. 7c-e). Taken together, MS \rightarrow MHb cholinergic projections modulate generalization
280 formation and extinction of visual aversion via M1 mAChRs on downstream glutamatergic/cholinergic
281 neurons.

282 **Discussion**

283 Our studies showed for the first time that MS cholinergic neurons were activated in visual aversion
284 generalization formation and silenced in its subsequent extinction as indicated by immunofluorescence
285 assay of c-Fos and fiber photometry of Ca $^{2+}$ signal, and apoptosis or inhibitions of MS cholinergic
286 neurons damaged generalization formation, whereas the activations of the MS disrupted its extinction
287 process. We also found that MS cholinergic neurons could project to the MHb, which indicates
288 existence of the MS \rightarrow MHb cholinergic circuit, and this circuit bidirectionally regulated generalization
289 and extinction in visual aversion, and blockade of M1 mAChRs rather than $\alpha 4\beta 2$ and $\alpha 7$ nAChRs on
290 MHb glutamatergic/cholinergic neurons weakened aversion generalization enhancement and
291 extinction deficiency caused by activation of MS \rightarrow MHb cholinergic circuits. Collectively, our results
292 provide strong evidence that the MS \rightarrow MHb cholinergic circuit is both sufficient and necessary to
293 rapidly mediate generalization formation and extinction in visual aversion (Fig. 8).

294 Formation and extinction are two important phases in generalization, and although generalization
295 is a critical function of the brain that supports survival and avoids danger, overgeneralization and
296 extinction dysfunction of aversion contributes to neurological diseases^{41, 42, 43, 44}. To explore
297 generalization processes, typically behavioral tasks based on contextual fear conditioning with electric
298 shock and auditory stimulus are always performed in animals^{45, 46}. However, the visual and auditory
299 systems frequently work together to facilitate the identification and localization of objects and events

300 in the external world, and for stimulus location, visual information is normally more accurate and
301 reliable and provides a reference for calibrating the perception of auditory space⁴⁷. A possible key role
302 of vision in the development of schizophrenia was reported in previous studies⁴⁸. Additionally, vision
303 is the primary sense humans use to evaluate and respond to threats, and human with high anxiety
304 showed increased visual scanning in response to threats as compared to healthy controls⁴⁹. Young- and
305 middle-age adults with worse visual function are at increased odds of having anxiety disorders⁵⁰.
306 Giving up contextual fear conditioning, we have established a novel procedure for induction of visual
307 aversion by a dynamic stripe image (aversive image) on digital screens in mice, and procedures of
308 aversion generalization formation and extinction are based on highly similarity between the dynamic
309 stripe image and its static stripe image (neutral image).

310 The cholinergic neurons constitute about 5% of the MS population, while the majority of MS
311 neurons are GABAergic and glutamatergic⁵¹. In the present study, we have shown for the first time
312 that MS cholinergic neurons are both sufficient and necessary to rapidly mediate visual aversion
313 generalization. MS projects to the hippocampus by septo-hippocampal pathways are always reported.
314 Previous studies have shown MS GABAergic projections to the dentate gyrus control adult
315 hippocampal neurogenesis⁵², and its glutamatergic projections drive hippocampal theta rhythms⁵³.
316 Here, after virus tracking MS cholinergic projections, we focus on the MS→MHb circuit and show
317 that MS→MHb cholinergic circuits rather than MS→CA3 projections in the hippocampus
318 bidirectionally regulate visual aversion generalization formation and extinction. The MHb, as an
319 epithalamic area controlling aversive physiological states, also regulates spatial learning and memory⁵⁴.
320 ⁵⁵. With chemogenetically activating and inhibiting approaches, we have shown that MS→MHb
321 cholinergic circuits mainly mediate aversion generalization rather than spatial working memory.

322 M1 mAChRs and $\alpha 4\beta 2$ and $\alpha 7$ nAChRs are commonly expressed in the brain and play key roles

323 in attention and memory¹⁵. M1 mAChRs signal mediated by $G_{q/11}$ while $\alpha 4\beta 2$ and $\alpha 7$ nAChRs signal
324 by ion channels. The distributions of M1, $\alpha 4$, $\alpha 7$ and $\beta 2$ polypeptides in the MHb are shown by in situ
325 hybridization from Allen Institute for Brain Science. Using M1 mAChRs antagonist^{56, 57} and $\alpha 4\beta 2$ and
326 $\alpha 7$ nAChRs antagonist⁵⁸, we have shown M1 mAChRs rather than $\alpha 4\beta 2$ and $\alpha 7$ nAChRs on
327 downstream neurons of MS→MHb cholinergic circuits mediate visual aversion generalization.
328 Previous studies have reported that MHb glutamatergic/cholinergic neurons control expressions of
329 aversive and fear memory^{26, 59}. Staining MHb neurons with ChAT and CaMKII α by
330 immunohistochemistry suggested that nearly all cholinergic neurons could corelease glutamate but a
331 part of MHb glutamatergic neurons could corelease acetylcholine. Activations of MHb
332 glutamatergic/cholinergic neurons weakened aversion generalization deficiency caused by inhibition
333 of MS→MHb cholinergic circuits, and M1 AChRs antagonist suppressed significant increase of
334 frequency and amplitude of EPSCs of the glutamatergic/cholinergic neurons under activating
335 MS→MHb cholinergic circuits. Based on these data, our studies have shown that MHb
336 glutamatergic/cholinergic neurons mediate regulatory effects of MS→MHb cholinergic circuits on
337 visual aversion generalization via m1 mAChRs. Because MHb glutamatergic/cholinergic neurons
338 mainly provide projections to the IPN and the MHb→IPN inputs play key roles in anxiety^{60, 61}, we
339 speculate that IPN might be a targeted region mediating generalization formation and extinction of
340 visual aversion following the MS→MHb cholinergic circuit.

341 Overall, taking advantage of virus tracking, optogenetic and chemogenetic approaches as well as
342 novel behavioral paradigm associated with visual aversion, we have identified MS→MHb cholinergic
343 circuit, and firstly provide highly consistent behavioral evidences for this circuit functions in
344 generalization formation and extinction of visual aversion. Therefore, these results strongly suggest
345 MS→MHb cholinergic circuit as new targets for therapeutically protecting against affective disorders

346 such as PTSD, anxiety disorders and etc.

347 **Methods**

348 **Animals.** Male SPF grade C57BL/6 mice (8–10 weeks old) provided by the Medical Center of
349 Yangzhou University (Yangzhou, China) were housed under conditions of a temperature of 20–24 °C,
350 a humidity of 55 ± 5%, and a 12 h/12 h cycle of illumination, during which animals were free to eat
351 and drink. Animal experiments were carried out in accordance with the ARRIVE (Animal Research:
352 Reporting of in Vivo Experiments) guidelines^{62, 63}. All methods were endorsed by the Institutional
353 Animal Care and Use Committee of China Pharmaceutical University.

354 **Virus.** AAVs used in this study were purchased from BrainVTA (Wuhan, China) and included
355 AAV2/9-chat-cre-2a-EGFP, AAV2/9-chat-cre, AAV2/9-Ef1 α -DIO-Gcamp6m, AAV(2/9 or 2/Retro)-
356 Ef1 α -DIO-hM4D(Gi)-mCherry, AAV(2/9 or 2/Retro)-Ef1 α -DIO-hM3D(Gq)-mCherry, AAV(2/9 or
357 2/Retro)-Ef1 α -DIO-eNpHR3.0-mCherry, AAV(2/9 or 2/Retro)-Ef1 α -DIO-hChR2(H134R)-mCherry,
358 AAV2/9-CAG-DIO-EGFP, AAV(2/9 or 2/Retro)-Ef1 α -DIO-mCherry, AAV2/9-Ef1 α -DIO-ACh2.0,
359 AAV2/9-CaMKII α -cre, AAV2/9-CaMKII α -hM4D(Gi)-mCherry, AAV2/9-chat-EGFP and AAV2/9-
360 CaMKII α -mCherry. AAV2/9-CAG-DIO-taCaspase3 was purchased from Taitool Bioscience
361 (Shanghai, China). Virus titer was shown in Supplementary Table 1.

362 **Drugs.** CNO purchased from the Sigma-Aldrich (Missouri, USA) was dissolved in saline (2.5 mg/kg)
363 for intraperitoneal injection while dissolved in artificial cerebrospinal fluid (ACSF, 3.0 μ M/0.1 μ l/side)
364 for stereotaxic injection. Benzethonium chloride purchased from Selleck Chemicals (Texas, USA) was
365 dissolved in ACSF (2.0 μ g/0.1 μ l/side) for stereotaxic injection to inhibit α 4 β 2 and α 7 nAChRs.
366 Pirenzepine dihydrochloride purchased from the MedChemExpress (New Jersey, USA) was dissolved
367 in ACSF (1.5 μ g/0.1 μ l/side for stereotaxic injection or 20 μ M for electrophysiological recording) to
368 block M1 mAChRs.

369 **Surgical procedures.** For stereotaxic injection of AAVs, mice were anaesthetized with isoflurane
370 (1.5-5%) and administered ketoprofen (5 mg/kg) for pain management. The scalp was incised to
371 expose the skull and connective tissue was gently scraped away. The AAVs were infused with a
372 volume of 300 nl into the MS or 100-200 nl per side into the MHb at 50 nl min⁻¹, respectively. The
373 injection coordinates (relative to bregma, mm): MS (anterior/posterior (AP): +0.86, medial/lateral
374 (ML): 0, dorsal/ventral (DV): -4.20), bilateral MHb (AP: -1.82, ML: ±0.20, DV: -2.50) and bilateral
375 CA3 (AP: -2.06, ML: ±2.4, DV: -2.2). At the end of the infusion, the injectors remained at the site
376 for 10 min to allow for virus diffusion. Skin covering the boreholes was sutured closed following
377 surgery. For fiber photometry and optogenetic experiments, optical fibres (200 µm core diameter, 0.37
378 NA; Inper, Hangzhou, China) threaded through 1.25 mm-wide wide ceramic ferrules (Inper) were
379 implanted into the MS or MHb (30° angle away from midline) 1 week before behavioral tasks,
380 respectively, and secured to the mouse skull with dental cement. Stainless steel guide cannulas (0.34
381 mm core diameter; RWD, Shenzhen, China) were bilaterally implanted into the MHb with the same
382 surgical approach for chemogenetic manipulations and drugs administrations. A total of 3–5 weeks
383 were to ensure for viral expression before behavioral tasks. Animals infused for electrophysiology
384 were maintained in their home cages for 6–8 weeks before recordings. Detailed strategy of virus
385 injection can be found in Supplementary Table 1.

386 **Immunohistochemistry.** For tissue preparation, mice were anaesthetized and transcardially perfused
387 with 50 ml PBS followed by 4% paraformaldehyde (PFA) in PBS. The brain was removed and
388 subsequently submerged into 4% PFA overnight before being cryoprotected in 30% sucrose solution
389 in PBS until they sank to the bottom of the container. Using a cryostat (CM3050S, Leica, Germany),
390 the frozen brains were sectioned into 30-µm coronal slices. Sections were washed in PBS three times
391 (5 min each) and incubated with blocking solution (10% normal donkey serum, 1% BSA, and 0.3%

392 Triton X-100 in PBS) for 1 h at the room temperature. Sections were subsequently incubated with
393 primary antibody in PBS overnight at 4 °C. The following primary antibodies were used: sheep anti-
394 ChAT (1:300, ab18736, Abcam, USA), rabbit anti-c-Fos (1:500, 226003, Synaptic Systems (SYSY),
395 Germany) and mouse anti-CaMKII (1:300, ab22609, Abcam, USA). After washing in PBS three times
396 (5 min each) and sections were incubated with fluorescein-labeled secondary antibody in PBS for 1 h.
397 The secondary antibodies were used: donkey anti-sheep Alexa Fluor 488 or 594 (1:1000, ab 150177
398 or ab 150180, Abcam, USA), donkey anti-rabbit Alexa Fluor 594 (1:1000, ab 150076, Abcam, USA)
399 and donkey anti-mouse Alexa Fluor 594 (1:1000, ab 150108, Abcam, USA). After washing in PBS
400 and staining with DAPI (C0065, Solarbio, Beijing, China), brain sections were mounted on positively
401 charged slides with prolong anti-fade medium. Fluorescent images were taken using a laser confocal
402 microscope (AiryScan LSM800, Zeiss, Germany) or fluorescence microscope (DM2000, Leica,
403 Germany). All images were taken in roughly the same imaging area and images were processed using
404 NIH ImageJ software. Sample size was based on reports in related literature and was not predetermined
405 by calculation.

406 **In vitro electrophysiological recording.** The methods of brain slice preparation and
407 electrophysiological recordings were similar to those in previous studies^{64, 65, 66}. In brief, after the full
408 expressions of AAVs, mice were anaesthetized with isoflurane and the brains were rapidly removed
409 and chilled in ice-cold sucrose solution containing (in mM): 40 NaCl, 4.5 KCl, 1.25 NaH₂PO₄, 25
410 NaHCO₃, 148.5 sucrose, 10 glucose, 1 ascorbic acid, 3 Na Pyruvate, 3 Myo Inositol, 0.5 CaCl₂ and 7
411 MgSO₄, pH 7.3, 315 mOsm. Coronal brain slices (300 µm) containing MS or MHb were prepared in
412 the same ice-cold sucrose solution using a vibratome (VT-1200s, Leica, Germany). Slices were then
413 incubated in warm (32–34 °C) sucrose solution for 30 min, and transferred to ACSF composed of (in
414 mM): 125 NaCl, 4.5 KCl, 1.25 NaH₂PO₄, 25 NaHCO₃, 15 sucrose, 15 glucose, 2.5 CaCl₂ and 1.3

415 MgSO₄, pH 7.3, 315 mOsm, and allowed to cool to room temperature before electrophysiological
416 recording. All solutions were continuously bubbled with 95% O₂/5% CO₂. Electrophysiological
417 recordings were made using a MultiClamp700B amplifier and PClamp software (Molecular Devices,
418 USA). The data were low-pass filtered at 2 kHz and digitized at 10 kHz with Digidata 1440 (Molecular
419 Devices, USA). During recording, slices were submerged in normal, oxygenated ACSF and superfused
420 (2 ml/min) at temperature (32–34 °C).

421 To identify MS cholinergic neurons, after expression of AAV2/9-chat-cre-2a-EGFP, spontaneous
422 action potentials (APs) of EGFP-labeled neurons in the MS were firstly recorded. Then APs were
423 recorded with intracellular current injection (+80 pA or -80pA, respectively) by whole-cell current
424 clamp. The pipette (3–5 MΩ) was pulled by a micropipette puller (P-97, Sutter instrument) and filled
425 with the internal solution (in mM: 105 K-gluconate, 5 NaCl, 10 HEPES, 2 MgATP, 0.5 NaGTP, and
426 0.2 EGTA, pH 7.3, 290 mOsm).

427 To confirm the functionality of expressed NpHR and hM3D(Gq), spontaneous firing of NpHR-
428 or hM3D(Gq)-expressing neurons in the MS were recorded by cell-attached voltage clamp. Following
429 a 3-min stabilization period, cell-attached voltage clamp was performed. And then, after 1 min
430 continuous recording, yellow-light (589 nm) was delivered to brain slices or CNO (5 μM) was added
431 to ACSF solution for the following recording.

432 To record EPSCs of MHb neurons, AAV2/9-CaMKIIα-mCherry and AAV2/9-chat-EGFP were
433 injected into the MHb. MHb glutamatergic neurons that corelease glutamate and acetylcholine
434 (MHb^{CaMKIIα+ChAT+}) were labeled with chat-EGFP and CaMKIIα-mCherry. MHb glutamatergic
435 neurons without releasing acetylcholine (MHb^{CaMKIIα+ChAT-}) were labeled with CaMKIIα-mCherry
436 alone. EPSCs were recorded by whole-cell voltage-clamp. Patch electrodes (3–5 MΩ) were filled with
437 pipette solution contained (in mM): 132.5 Cs-gluconate, 17.5 CsCl, 2 MgCl₂, 0.5 EGTA, 10 HEPES,

438 4 ATP, 5 QX-314, pH 7.3, 290-300 mOsm). For voltage-clamp recordings, EPSCs were recorded at
439 -70 mV. After expressions of AAV2/9-chat-cre and AAV2/9-Ef1 α -DIO-ChR2-mCherry in the MS,
440 for the photostimulation of ChR2-expression axon terminals, a blue light pulse was emitted from a
441 Lambda DG-4 (Sutter, USA) under the control of Digidata 1440. A Lambda DG-4 Wavelength
442 Switcher was used to deliver different wavelengths of light through the $40\times$ objective. Following a 3-
443 min stabilization period, sEPSCs of MHb glutamatergic neurons were firstly continuous recorded for
444 1 min, and then blue-light (465 nm, 5 ms, 20 Hz) was delivered to the MHb slices for the following
445 light-evoked EPSC recording. Additionally, M1 mAChRs antagonist pirenzepine dihydrochloride (20
446 μ M) was added to ACSF solution for the last recording. Amplitude and frequency of EPSCs were
447 analyzed with Clampfit 11.1 software.

448 **Apparatus for fiber photometry and optogenetic experiments.** After the expressions of AAV2/9-
449 EF1 α -DIO-Gcamp6m in the MS and AAV2/9-Ef1 α -DIO-ACh2.0 in the MHb, fiber photometry
450 system (Inper) was used to record GCaMP and acetylcholine fluorescence signals. Firstly, laser beam
451 from a 470-nm laser (B1470; Inper) was reflected by a dichroic mirror (MD498; Thorlabs, USA),
452 focused by a $\times 10$ objective lens (NA = 0.3; Olympus, Japan) and then coupled to an optical commutator
453 (Inper). An optical fiber (230 μ m O.D., NA = 0.37, 1 m long) guided the light between the commutator
454 and the implanted optical fiber. The laser power was adjusted at the tip of optical fiber to a low level
455 of 0.01-0.02 mW, to minimize bleaching. Then the fluorescence was bandpass filtered (MF525-39,
456 Thorlabs) and focused by a 20 times objective lens and the fluorescence signal was collected by CMOS
457 camera. The end of the fiber was imaged at the frame rate from 1-320. The ROI area size and mean
458 value were set through Inper Studio. 470 nm and 410 nm light sources were given alternately, and 410
459 nm was used as the control.

460 For optogenetic experiments, light was delivered to the MS or the MHb via a laser (Inper)
461 connected through a ceramic mating sleeve (Inper) to the ferrule implanted on the mice. A 589-nm
462 laser was used to inhibit MS cholinergic neurons or their terminals at bilateral MHb in NpHR-
463 expressing mice. Yellow light intensity was delivered at 10 mW. Meanwhile, a 465-nm laser was used
464 to activate MS cholinergic neurons or their terminals at bilateral MHb in ChR2-expressing mice. 10-
465 40 ms blue light pulses were delivered at 20 Hz.

466 **Behavioral protocols**

467 *Visual aversion task.* The apparatus consisted of a two-compartment (50 cm × 25 cm × 25 cm for each
468 chamber) blue plastic box. The dividing wall was made from non-transparent blue plastic with a
469 rectangular opening (10 cm in width) in the middle to enable mice free access to each chamber. Each
470 chamber was filled with four digital screens (9.7-inch, resolution: 2048 × 1536 dpi) on its three walls
471 (except dividing wall). In the task, mice were first habituated to the two-chamber apparatus for 10 min
472 while all digital screens were off. Then in test phase, four digital screens in each chamber displayed
473 one of three images: a blank image (image format: JPG), a static stripe image (image format: JPG) and
474 the same stripe image that was moving (named as dynamic stripe image, image format: GIF, five
475 frames per image, all frame delays 3 with GIF Movie Gear software), and mice were placed in the two-
476 chamber apparatus for a 5-min real-time place preference (RTPP) test. Visual aversion behavior for an
477 image was defined by the percentage of time spent in each image chamber.

478 *Aversion generalization task.* The task protocol was made referring to previous studies^{32, 33, 34, 35}. The
479 same two-chamber apparatus was used in aversion generalization task. The task involved five phases,
480 including two habituation phases, one training phase, and two test phases. In habituation phase 1, mice
481 were placed in the apparatus with all eight digital screens off for a 10-min habituation. 1 h later, in
482 habituation phase 2, mice were placed in the apparatus that one chamber showed same blank images

483 whereas the other chamber showed same static stripes image on screens for a 10 min habituation. 1 h
484 later, in training phase, mice were placed in the apparatus with all two chambers displaying
485 corresponding dynamic stripe images identified as aversive images for a 10-min visual stimulation.
486 After a 1-h delay in test phase 1, mice were placed again in the apparatus that one chamber showed
487 blank images whereas the other chamber showed static stripe images for a 5-min RTPP-test. After a
488 4-h delay in test phase 2, mice were placed in the apparatus for a 5-min RTPP-test in the same condition
489 with test phase 1. Visual aversion behavior was defined by the percentage of time spent in each
490 chamber.

491 *Open field test (OFT)*. Each mouse was placed in the open field chamber (a plastic box with dimensions
492 of 50 cm × 50 cm × 40 cm divided into 144 squares), and time spent in the center was assessed for 5
493 min using video camera and software to record and analyze paths. Anxiety-like behavior was defined
494 by the time spent in the central zone.

495 *Elevated plus-maze (EPM) test*. Each mouse was placed in the center of the EPM and videotaped for
496 5 min. The time spent in two open arms (30 cm × 5 cm) and two closed arms (30 cm × 5 cm × 20 cm)
497 were determined from the video recording by blinded observers. Anxiety-like behavior was defined
498 by the time spent in the open arms.

499 *Grip strength test (GST)*. Forelimb grip strength was measured as tension force using a computerized
500 grip strength meter (GSM)⁶⁷. Each mouse was lifted over the baseplate by its tail, and its forepaws
501 allowed to grasp the steel grip. The tail of each mouse was then placed in the center of alignment tool
502 and the mouse was then gently pulled backward by the tail until its grip was released. The GSM was
503 then used to measure the maximal force (N) before the mouse released the bar. Three trials were
504 performed for each mouse with a 2-min resting period between trials.

505 *Novel object recognition test (NORT)*. NORT is accomplished within three days and consists of a
506 habituation, training, and testing session. The first day was the habituation session in which mice were
507 allowed to move freely in a rectangular plastic box (50 cm × 50 cm × 40 cm). On the second day
508 (training session), the mice were allowed to explore two identical objects for 5 min. On the third day
509 (testing session), one of the objects was changed to a new object (different color and shape), and the
510 mice were allowed to explore for 5 min. The time spent exploring, defined as mouth, nose, or paw less
511 than 2 cm away from the object, was recorded by the computer. The discrimination index, or the
512 difference in exploration time for novel object minus the familiar object divided by the total amount
513 of exploration of both objects, was assessed.

514 *Morris water maze (MWM) test*. Each mouse was placed in a round pool (1.2 m diameter, 0.5 m height)
515 filled with water to a 0.3 m depth at a temperature of 25 °C. An escape platform with a diameter of 9
516 cm was placed at the midpoint of any quadrant of the pool, and visual cues were located around the
517 room. The test consisted of five days training period with visible and hidden platform. The escape
518 platform always stayed at a fixed position during the entire duration of training (5 days). On every trial,
519 mice were put into the pool facing the pool wall. The visible platform training sessions were performed
520 on days 1 and 2. During visible training trials, a small flag was affixed to the platform that was 1 cm
521 below the surface of the water. Hidden platform training sessions in which the small flag was removed
522 but the position of the platform remained the same were performed on days 3-5. There were four trials
523 per day, each lasting 90 s, with an intertrial interval of 1 hour. Once on the platform, the trial end after
524 10 s. If the mouse failed to find the platform after 90 s, it would gently guide to the platform and left
525 for 30 s before being removed. The time to find the platform (escape latency) was compared. On the
526 final day (day 6), during the probe trial, mice were allowed to swim for 90 s while the platform is taken
527 away. The number of times of each individual mouse passing the escape platform location and the time

528 spent in the target quadrant were recorded and processed using video tracking device and computer-
529 equipped analytics management system.

530 *Y-maze test.* Spontaneous alternation behavior was evaluated in a symmetrical Y-maze (3 arms, 40 cm
531 \times 9 cm \times 16 cm). Arm choices (all four paws entering one arm) were recorded during an 8-min
532 exploration trial in the Y-shaped maze by a video camera. Alternation was defined by recording the
533 order of the visited arms (A, B, or C). Overlapping triplets of 3-arm visits was counted as one complete
534 spontaneous alternation. The percentage of spontaneous alternation was calculated according to the
535 following calculation: (number of spontaneous alternation) / (total number of arm visits – 2).

536 **Statistical analysis.** All experiments and data analyses were conducted blinded, including the
537 immunohistochemistry and behavioral analyses. SPSS (version 17.0) was used for statistical analysis
538 as indicated in the figure legends. All data are shown as mean \pm standard error of mean (SEM).
539 Statistical significance was assessed by two-tailed unpaired Student's *t* test or one-way ANOVA
540 followed by a Tukey's post-hoc analysis for multiple comparisons. $P < 0.05$ was considered
541 statistically significant. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, n.s.: $P > 0.05$.

542

543

544

545

546

547

548

549

550

References

- 551 1. Shalev A, Liberzon I, Marmar C. Post-Traumatic Stress Disorder. *New Engl J Med* **376**, 2459-
552 2469 (2017).
- 553
554 2. LeDoux JE. Emotion circuits in the brain. *Annu Rev Neurosci* **23**, 155-184 (2000).
- 555
556 3. Marsicano G, *et al.* The endogenous cannabinoid system controls extinction of aversive
557 memories. *Nature* **418**, 530-534 (2002).
- 558
559 4. Onat S, Buchel C. The neuronal basis of fear generalization in humans. *Nat Neurosci* **18**, 1811-
560 1818 (2015).
- 561
562 5. Parsons RG, Ressler KJ. Implications of memory modulation for post-traumatic stress and fear
563 disorders. *Nat Neurosci* **16**, 146-153 (2013).
- 564
565 6. Yehuda R, *et al.* Post-traumatic stress disorder. *Nat Rev Dis Primers* **1**, (2015).
- 566
567 7. McGuire JF, Orr SP, Essoe JKY, McCracken JT, Storch EA, Piacentini J. Extinction learning
568 in childhood anxiety disorders, obsessive compulsive disorder and post-traumatic stress
569 disorder: implications for treatment. *Expert Rev Neurother* **16**, 1155-1174 (2016).
- 570
571 8. Drew MR, Huckleberry KA. Modulation of Aversive Memory by Adult Hippocampal
572 Neurogenesis. *Neurotherapeutics* **14**, 646-661 (2017).
- 573
574 9. Ozawa T, *et al.* A feedback neural circuit for calibrating aversive memory strength. *Nat*
575 *Neurosci* **20**, 90-97 (2017).
- 576
577 10. Vanz F, Bicca MA, Linartevichi VF, Giachero M, Bertoglio LJ, de Lima TCM. Role of dorsal
578 hippocampus kappa opioid receptors in contextual aversive memory consolidation in rats.
579 *Neuropharmacology* **135**, 253-267 (2018).
- 580
581 11. Chen JY, Campos CA, Jarvie BC, Palmiter RD. Parabrachial CGRP Neurons Establish and
582 Sustain Aversive Taste Memories. *Neuron* **100**, 891-+ (2018).
- 583
584 12. Slouzkey I, Rosenblum K, Maroun M. Memory of Conditioned Taste Aversion Is Erased by
585 Inhibition of PI3K in the Insular Cortex. *Neuropsychopharmacol* **38**, 1143-1153 (2013).
- 586
587 13. Hampel H, *et al.* The cholinergic system in the pathophysiology and treatment of Alzheimer's
588 disease. *Brain* **141**, 1917-1933 (2018).
- 589
590 14. Raza SA, *et al.* HIPP neurons in the dentate gyrus mediate the cholinergic modulation of
591 background context memory salience. *Nat Commun* **8**, 189 (2017).
- 592
593 15. Ballinger EC, Ananth M, Talmage DA, Role LW. Basal Forebrain Cholinergic Circuits and
594 Signaling in Cognition and Cognitive Decline. *Neuron* **91**, 1199-1218 (2016).
- 595

596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638

16. Jiang L, *et al.* Cholinergic Signaling Controls Conditioned Fear Behaviors and Enhances Plasticity of Cortical-Amygdala Circuits. *Neuron* **90**, 1057-1070 (2016).

17. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. *J Comp Neurol* **214**, 170-197 (1983).

18. Woolf NJ. Cholinergic systems in mammalian brain and spinal cord. *Prog Neurobiol* **37**, 475-524 (1991).

19. Jiang YY, Zhang Y, Cui S, Liu FY, Yi M, Wan Y. Cholinergic neurons in medial septum maintain anxiety-like behaviors induced by chronic inflammatory pain. *Neurosci Lett* **671**, 7-12 (2018).

20. Zhang Y, *et al.* Inhibiting medial septal cholinergic neurons with DREADD alleviated anxiety-like behaviors in mice. *Neurosci Lett* **638**, 139-144 (2017).

21. Staib JM, Della Valle R, Knox DK. Disruption of medial septum and diagonal bands of Broca cholinergic projections to the ventral hippocampus disrupt auditory fear memory. *Neurobiol Learn Mem* **152**, 71-79 (2018).

22. Agetsuma M, *et al.* The habenula is crucial for experience-dependent modification of fear responses in zebrafish. *Nat Neurosci* **13**, 1354-1356 (2010).

23. McLaughlin I, Dani JA, De Biasi M. The medial habenula and interpeduncular nucleus circuitry is critical in addiction, anxiety, and mood regulation. *J Neurochem* **142**, 130-143 (2017).

24. Yamaguchi T, Danjo T, Pastan I, Hikida T, Nakanishi S. Distinct Roles of Segregated Transmission of the Septo-Habenular Pathway in Anxiety and Fear. *Neuron* **78**, 537-544 (2013).

25. Boulos LJ, *et al.* Mu opioid receptors in the medial habenula contribute to naloxone aversion. *Neuropsychopharmacology* **45**, 247-255 (2020).

26. Soria-Gomez E, *et al.* Habenular CB1 Receptors Control the Expression of Aversive Memories. *Neuron* **88**, 306-313 (2015).

27. Paul S, Jeon WK, Bizon JL, Han JS. Interaction of basal forebrain cholinergic neurons with the glucocorticoid system in stress regulation and cognitive impairment. *Front Aging Neurosci* **7**, 43 (2015).

- 639 28. Shalev L, Paz R, Avidan G. Visual Aversive Learning Compromises Sensory Discrimination.
640 *The Journal of neuroscience : the official journal of the Society for Neuroscience* **38**, 2766-
641 2779 (2018).
- 642
- 643 29. Blechert J, Michael T, Vriends N, Margraf J, Wilhelm FH. Fear conditioning in posttraumatic
644 stress disorder: evidence for delayed extinction of autonomic, experiential, and behavioural
645 responses. *Behav Res Ther* **45**, 2019-2033 (2007).
- 646
- 647 30. Lopresto D, Schipper P, Homberg JR. Neural circuits and mechanisms involved in fear
648 generalization: Implications for the pathophysiology and treatment of posttraumatic stress
649 disorder. *Neurosci Biobehav Rev* **60**, 31-42 (2016).
- 650
- 651 31. O'Malley KR, Waters AM. Attention avoidance of the threat conditioned stimulus during
652 extinction increases physiological arousal generalisation and retention. *Behav Res Ther* **104**,
653 51-61 (2018).
- 654
- 655 32. Aqrabawi AJ, Kim JC. Hippocampal projections to the anterior olfactory nucleus differentially
656 convey spatiotemporal information during episodic odour memory. *Nature communications* **9**,
657 2735 (2018).
- 658
- 659 33. Shen CJ, *et al.* Cannabinoid CB1 receptors in the amygdalar cholecystokinin glutamatergic
660 afferents to nucleus accumbens modulate depressive-like behavior. *Nature medicine* **25**, 337-
661 349 (2019).
- 662
- 663 34. Song J, *et al.* Crucial role of feedback signals from prelimbic cortex to basolateral amygdala in
664 the retrieval of morphine withdrawal memory. *Science advances* **5**, eaat3210 (2019).
- 665
- 666 35. Xu Y, *et al.* Identification of a neurocircuit underlying regulation of feeding by stress-related
667 emotional responses. *Nature communications* **10**, 3446 (2019).
- 668
- 669 36. Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR. Identification and localization of
670 muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. *J*
671 *Neurosci* **11**, 3218-3226 (1991).
- 672
- 673 37. Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their
674 relevance. *Trends Pharmacol Sci* **27**, 482-491 (2006).
- 675
- 676 38. Koppensteiner P, Galvin C, Ninan I. Development- and experience-dependent plasticity in the
677 dorsomedial habenula. *Mol Cell Neurosci* **77**, 105-112 (2016).
- 678
- 679 39. Jing M, *et al.* A genetically encoded fluorescent acetylcholine indicator for in vitro and in vivo
680 studies. *Nat Biotechnol* **36**, 726-737 (2018).
- 681
- 682 40. Ren J, *et al.* Habenula "cholinergic" neurons co-release glutamate and acetylcholine and
683 activate postsynaptic neurons via distinct transmission modes. *Neuron* **69**, 445-452 (2011).

684

- 685 41. Berg H, *et al.* Salience and central executive networks track overgeneralization of conditioned-
686 fear in post-traumatic stress disorder. *Psychol Med*, 1-10 (2020).
- 687
- 688 42. De Bundel D, Zussy C, Espallergues J, Gerfen CR, Girault JA, Valjent E. Dopamine D2
689 receptors gate generalization of conditioned threat responses through mTORC1 signaling in
690 the extended amygdala. *Mol Psychiatry* **21**, 1545-1553 (2016).
- 691
- 692 43. Kaczurkin AN, *et al.* Neural Substrates of Overgeneralized Conditioned Fear in PTSD. *Am J*
693 *Psychiatry* **174**, 125-134 (2017).
- 694
- 695 44. Lissek S, Kaczurkin AN, Rabin S, Geraci M, Pine DS, Grillon C. Generalized anxiety disorder
696 is associated with overgeneralization of classically conditioned fear. *Biol Psychiatry* **75**, 909-
697 915 (2014).
- 698
- 699 45. Rudy JW, Huff NC, Matus-Amat P. Understanding contextual fear conditioning: insights from
700 a two-process model. *Neurosci Biobehav Rev* **28**, 675-685 (2004).
- 701
- 702 46. Izquierdo I, Furini CR, Myskiw JC. Fear Memory. *Physiol Rev* **96**, 695-750 (2016).
- 703
- 704 47. King AJ. Visual influences on auditory spatial learning. *Philos Trans R Soc Lond B Biol Sci*
705 **364**, 331-339 (2009).
- 706
- 707 48. Csaszar N, Kapocs G, Bokkon I. A possible key role of vision in the development of
708 schizophrenia. *Rev Neurosci* **30**, 359-379 (2019).
- 709
- 710 49. Yilmaz Balban M, *et al.* Human Responses to Visually Evoked Threat. *Curr Biol*, (2020).
- 711
- 712 50. Loprinzi PD, Codey K. Influence of visual acuity on anxiety, panic and depression disorders
713 among young and middle age adults in the United States. *J Affect Disord* **167**, 8-11 (2014).
- 714
- 715 51. Gritti I, Henny P, Galloni F, Mainville L, Mariotti M, Jones BE. Stereological estimates of the
716 basal forebrain cell population in the rat, including neurons containing choline acetyltransferase,
717 glutamic acid decarboxylase or phosphate-activated glutaminase and colocalizing vesicular
718 glutamate transporters. *Neuroscience* **143**, 1051-1064 (2006).
- 719
- 720 52. Bao H, *et al.* Long-Range GABAergic Inputs Regulate Neural Stem Cell Quiescence and
721 Control Adult Hippocampal Neurogenesis. *Cell Stem Cell* **21**, 604-617 e605 (2017).
- 722
- 723 53. Robinson J, *et al.* Optogenetic Activation of Septal Glutamatergic Neurons Drive Hippocampal
724 Theta Rhythms. *J Neurosci* **36**, 3016-3023 (2016).
- 725
- 726 54. Kobayashi Y, *et al.* Genetic dissection of medial habenula-interpeduncular nucleus pathway
727 function in mice. *Frontiers in behavioral neuroscience* **7**, 17 (2013).
- 728

- 729 55. Lecourtier L, Neijt HC, Kelly PH. Habenula lesions cause impaired cognitive performance in
730 rats: implications for schizophrenia. *The European journal of neuroscience* **19**, 2551-2560
731 (2004).
732
- 733 56. Sharma VK, *et al.* Molecular and functional identification of m1 muscarinic acetylcholine
734 receptors in rat ventricular myocytes. *Circ Res* **79**, 86-93 (1996).
735
- 736 57. Wu W, Li H, Liu Y, Huang X, Chen L, Zhai H. Involvement of insular muscarinic cholinergic
737 receptors in morphine-induced conditioned place preference in rats. *Psychopharmacology*
738 (*Berl*) **231**, 4109-4118 (2014).
739
- 740 58. Coates KM, Flood P. Ketamine and its preservative, benzethonium chloride, both inhibit
741 human recombinant alpha7 and alpha4beta2 neuronal nicotinic acetylcholine receptors in
742 *Xenopus* oocytes. *Br J Pharmacol* **134**, 871-879 (2001).
743
- 744 59. Zhang J, *et al.* Presynaptic Excitation via GABAB Receptors in Habenula Cholinergic Neurons
745 Regulates Fear Memory Expression. *Cell* **166**, 716-728 (2016).
746
- 747 60. Zhao-Shea R, *et al.* Increased CRF signalling in a ventral tegmental area-interpeduncular
748 nucleus-medial habenula circuit induces anxiety during nicotine withdrawal. *Nat Commun* **6**,
749 6770 (2015).
750
- 751 61. Molas S, DeGroot SR, Zhao-Shea R, Tapper AR. Anxiety and Nicotine Dependence: Emerging
752 Role of the Habenulo-Interpeduncular Axis. *Trends Pharmacol Sci* **38**, 169-180 (2017).
753
- 754 62. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, Group NCRRGW. Animal
755 research: reporting in vivo experiments: the ARRIVE guidelines. *Br J Pharmacol* **160**, 1577-
756 1579 (2010).
757
- 758 63. McGrath JC, Lilley E. Implementing guidelines on reporting research using animals (ARRIVE
759 etc.): new requirements for publication in BJP. *Br J Pharmacol* **172**, 3189-3193 (2015).
760
- 761 64. Ma T, *et al.* Bidirectional and long-lasting control of alcohol-seeking behavior by corticostriatal
762 LTP and LTD. *Nat Neurosci* **21**, 373-383 (2018).
763
- 764 65. Zou WJ, *et al.* A discrete serotonergic circuit regulates vulnerability to social stress. *Nat*
765 *Commun* **11**, 4218 (2020).
766
- 767 66. Liang HY, *et al.* nNOS-expressing neurons in the vmPFC transform pPVT-derived chronic
768 pain signals into anxiety behaviors. *Nat Commun* **11**, 2501 (2020).
769
- 770 67. Liu K, *et al.* Lhx6-positive GABA-releasing neurons of the zona incerta promote sleep. *Nature*
771 **548**, 582-587 (2017).
772
- 773

774 **Acknowledgements**

775 This work was supported by grants from the National Natural Science Foundation of China (81773714
776 and 81573413 to Hao Hong) and the “Double First-Class” University Project (CPU2018GF/GY**).
777 We acknowledge technical support by the Public Experimental Pharmacology Platform of China
778 Pharmaceutical University, and appreciate Dr. Miranda N. Reed and Prof. Vishnu Suppiramaniam
779 from Auburn University for their conceptual suggestion and language assistance.

780 **Author contributions**

781 H.H., S.-S.T. and R.-H.M. carried out the study conceptualization and experimental design. R.-H.M.
782 performed apoptosis, chemogenetic, and optogenetic studies. R.-H.M. and X.-M.H. performed
783 synaptic tracing and in vivo fiber photometry. X.-M.H. and H.W. performed virus vectors injections
784 and immunohistochemistry. Y.L. and D.-H.Y. performed imaging and cell counting. H.H. and R.-H.M.
785 wrote the manuscript. S.-S.T. and H.W. revised the manuscript. All authors contributed to the data
786 analysis and presentation in the paper.

787 **Competing interests**

788 The authors declare no competing interests.

789

790

791

792


793

794

795

796

797 **Figure. 1**



821 **Fig. 1 MS provides strong cholinergic projections to the MHb.** **a** Schematic diagram of virus
 822 injection of AAV-chat-cre-EGFP into the MS to track its cholinergic projections. **b** Representative
 823 images of AAV-chat-cre-EGFP expression in the MS three weeks after virus injection. The numbers

824 correspond to anterior-posterior distance (in mm) from bregma. **c** Representative image of EGFP-
825 labeled cholinergic neurons (green) stained with anti-ChAT (red) in the MS by immunohistochemistry.
826 Inset, magnification of targeted neuron marked with a white arrow. **d** Quantification of the percentage
827 of ChAT⁺ EGFP⁺ cells (blue) relative to all EGFP-labeled cholinergic neurons in the MS.
828 Quantification of the percentage of ChAT⁺ EGFP⁺ cells (red) relative to all anti-ChAT neurons in the
829 MS. *n* = 5, four sections per mouse. **e** Representative image of EGFP-labeled MS cholinergic neurons
830 in whole-cell patch-clamp recording after a 6-8 weeks expression of AAV-chat-cre-EGFP. **f** Response
831 of EGFP-labeled MS cholinergic neurons to intracellular current steps during whole-cell recording.
832 Depolarizing current: +80 pA; hyperpolarization current: -80 pA. **g** Representative whole-brain
833 mapping of EGFP-labeled cholinergic projections from the MS to the MHb. Scale bar, 400 μm (**b**),
834 100 μm (**c**), 50 μm (**e**), 400 μm (**g**, middle) and 50 μm (**g**, right). Data are mean ± s.e.m. Additional
835 statistical information can be found in Supplementary Table 2.

836

837

838

839

840

841

842


843




844


845

846

847 **Figure. 2**







915 **Fig. 2 MS cholinergic neuron supports rapid generalization formation and extinction of visual**
 916 **aversion in mice. a** Scheme of a visual aversion task based on real-time place preference (RTPP)
 917 caused by vision. Red arrows show movement direction of the dynamic stripe image. **b** Representative
 918 trace of the locomotion in visual aversion task in mice. **c** Quantification of the percentage of time spent
 919 (**c**, left) or distance moved (**c**, right) in each chamber during test phase. $n = 15$. **d** Scheme of a


920 generalization task with visual aversion stimulus during training phase. **e, f** Representative movement
921 trace and quantification of the percentage of time spent in each chamber in test phase 1 and 2 (test
922 phase 1: generalization formation phase of visual aversion, **e**; test phase 2: generalization extinction
923 phase, **f**). $n = 50$. **g** Scheme of a generalization task without visual aversion stimulus during training
924 phase. **h, i** Representative movement trace and quantification of the percentage of time spent (by mice
925 without suffering aversion stimulus) in each chamber in test phase 1 and 2. $n = 30$. **j** Representative
926 images of ChAT and c-Fos immunostaining in MS neurons of mice subjected to aversion generalization
927 task. **k** Quantification of c-Fos⁺ ChAT⁺ neurons in the MS. $n = 5$, four sections per mouse. **l** Schematic
928 diagram of virus injections and optic fiber implantation for recording of GCaMP6m fluorescence signals
929 of MS cholinergic neurons. **m** Representative images of GCaMP6m expression in the MS. **n** Schematic
930 diagram of the fiber photometry setup. Ca²⁺ transients were recorded from GCaMP6m-expressing MS
931 cholinergic neurons in mice subjected to visual aversion generalization task. **o, p** Upper panel: the
932 heatmap illustration of Ca²⁺ signals aligned to the onset of aversion generalization formation or
933 extinction assessment. Each row represents one bout. Lower panel: the peri-event plot of the average
934 Ca²⁺ signal transients. 0 s means time from mice first entering the chamber with stripe images onset.
935 $n = 10$. Thick red lines indicate mean and shaded areas indicate SEM. Mice with aversion stimulus (**o**),
936 mice without aversion stimulus (**p**). Scale bar, 200 μm (**j**), 400 μm (**m**, top) and 50 μm (**m**, bottom).
937 Data are mean \pm s.e.m. $**P < 0.01$, $***P < 0.001$ (two-tailed unpaired Student's t test for **c, e, f, h** and
938 **i**; one-way ANOVA with Tukey's post-hoc analysis for **k**). Exact p values and additional statistical
939 information can be found in Supplementary Table 2.

940




941

942


943 **Figure. 3**






968

g**h****i**

977

j

983

k**l****m**

994

995

n

996

997

998

999

1000

1001

1002

1003

1004

1005

1006

1007

1008

1009

1010

1011

1012

1013

1014

1015

1016

1017

1018




Fig. 3 MS cholinergic neuron activity is necessary for generalization formation and extinction of

visual aversion. a Schematic diagram depicting virus injections for apoptosis of MS cholinergic

neurons. **b, c** Representative images (**b**) and quantification (**c**) of EGFP-labeled MS cholinergic

neurons in taCaspase3-expressing or control mice. $n = 5$, four sections per mouse. **d, e** Data of visual

aversion generalization task in mice whose MS cholinergic neurons were inhibited with apoptosis

manipulation (representative trace of mice, **d**; quantification of the percentage of time spent in each

chamber during generalization formation and extinction phases, **e**). $n = 15$. **f** Scheme of visual aversion

generalization task with optogenetic inhibition approach using a yellow-light (589 nm, 10 mW). **g**

Schematic diagram depicting virus injections for optogenetic inhibition of MS cholinergic neurons. **h**

Yellow light decreased spontaneous firing in MS cholinergic neurons expressing NpHR-mCherry in

brain slices. $n = 12$ cells from four mice. **i, j** Data of visual aversion generalization task in mice whose

MS cholinergic neurons were inhibited with optogenetic manipulation (representative trace of mice, **i**;

quantification of the percentage of time spent in each chamber during generalization phases, **j**). $n = 15$.

k Schematic diagram depicting virus injections for chemogenetic activation of MS cholinergic neurons.

l Bath application of CNO (5 μ M) increased spontaneous firing in MS cholinergic neurons expressing

hM3Dq-mCherry in brain slices. $n = 12$ cells from four mice. **m, n** Data of visual aversion

1019 generalization task in mice whose MS cholinergic neurons were activated with chemogenetic
1020 manipulation (representative trace of mice, **m**; quantification of the percentage of time spent in each
1021 chamber during generalization phases, **n**). Mice were intraperitoneally injected with CNO (2.5 mg/kg)
1022 after generalization formation test. $n = 15$. Scale bar, 200 μm (**b**). Data are mean \pm s.e.m. $*P < 0.05$, $**P$
1023 < 0.01 , $***P < 0.001$, n.s.: $p > 0.05$ (two-tailed unpaired Student's t test for **c**, **h** and **l**; one-way ANOVA
1024 with Tukey's post-hoc analysis for **e**, **j** and **n**). Exact p values and additional statistical information can
1025 be found in Supplementary Table 2.

1026

1027

1028

1029

1030

1031

1032

1033

1034

1035

1036

1037

1038

1039

1040

1041

Figure. 4

1042

1043

1044

1045

1046

1047

1048

1049

1050

1051

1052

1053

1054

1055

1056

1057

1058

1059

1060

1061


1062

1063

1064

1065

1066



1067 **Fig. 4 MS→MHb cholinergic circuit drives generalization formation and extinction of visual**
1068 **aversion. a** Schematic diagram depicting virus injections for chemogenetic inhibition of MS→MHb
1069 cholinergic circuits. **b** Representative image of AAVs expression in the MHb three weeks after AAV-
1070 hM4D(Gi) injection. **c, d** Data of visual aversion generalization task in mice whose MS→MHb
1071 cholinergic circuits were inhibited with chemogenetic manipulation (representative trace of mice, **c**;
1072 quantification of the percentage of time spent in each chamber during generalization formation and
1073 extinction phases, **d**). Mice were intraperitoneally injected with CNO (2.5 mg/kg) 30 min before
1074 generalization formation test. $n = 15$. **e** Scheme of visual aversion generalization task with an
1075 optogenetic activation approach using blue-light pulse (465 nm, 20 Hz, 40 ms). **f** Schematic diagram
1076 depicting virus injections for optogenetic activation of MS→MHb cholinergic circuits. **g**
1077 Representative image of AAVs expression in the MHb three weeks after AAV-ChR2 injection. **h, i** Data
1078 of visual aversion generalization task in mice whose MS→MHb cholinergic circuits were activation
1079 with optogenetic manipulation (representative trace of mice, **h**; quantification of the percentage of time
1080 spent in each chamber during generalization formation and extinction phases, **i**). Scale bar, 100 μm (**b**
1081 and **g**). Data are mean \pm s.e.m. $*P < 0.05$, $**P < 0.01$, $***P < 0.001$, n.s.: $p > 0.05$ (one-way ANOVA
1082 with Tukey's post-hoc analysis for **d** and **i**). Exact p values and additional statistical information can
1083 be found in Supplementary Table 2.

1084

1085

1086

1087

1088

1089

Figure. 5

1090

1091

1092

1093

1094

1095

1096

1097

1098

1099

1100

1101

1102

1103

1104

1105

1106

1107

1108

1109

1110

1111


1112

1113


1114

1115


a




c




b




d




e



f



g





1116 **Fig. 5 M1 mAChRs and glutamatergic neurons in the MHb are involved in generalization**
1117 **formation and extinction of visual aversion. a** Schematic diagram depicting virus and drug injections
1118 for chemogenetic activation of MS→MHb cholinergic circuits and blockade of MHb M1 mAChRs. **b**
1119 Representative image of AAVs expression in the MHb three weeks after AAV-hM3D(Gq) injection. **c,**
1120 **d** Data of visual aversion generalization task in mice whose MS→MHb cholinergic circuits were
1121 activated with chemogenetic manipulation while MHb M1 mAChRs were blocked by pirenzepine
1122 (representative trace of mice, **c**; quantification of the percentage of time spent in each chamber during
1123 generalization formation and extinction phases, **d**). Mice were injected with CNO (3.0 μM/0.1 μL/side)
1124 or CNO + Pirenzepine (1.5 μg/0.1 μL/side) into the MHb by cannulas 30 min before generalization
1125 formation test. $n = 10$. **e** Schematic diagram of virus injections and optic fiber implantation for
1126 recording of acetylcholine fluorescence signals of MHb glutamatergic neurons. **f** Representative
1127 images of ACh2.0 expression in the MHb three weeks after AAV-ACh2.0 injection. **g** Acetylcholine
1128 transmissions in MHb glutamatergic neurons were involved in generalization formation (**g**, left) and
1129 extinction (**g**, right) of visual aversion. Upper panel, the heatmap illustration of acetylcholine signals
1130 aligned to the onset of individual generalization assessments. Each row represents one bout, and a total
1131 of 10 bouts are illustrated. Lower panel, the peri-event plot of the average acetylcholine signal
1132 transients. 0 s means time from mice first entering the chamber with stripe images onset. $n = 10$. Thick
1133 red lines indicate mean and shaded areas indicate SEM. Scale bar, 100 μm (**b**), 200 μm (**f**, left) and 50
1134 μm (**f**, right). Data are mean ± s.e.m. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, n.s.: $p > 0.05$ (one-way
1135 ANOVA with Tukey's post-hoc analysis for **d**). Exact p values and additional statistical information
1136 can be found in Supplementary Table 2.

1137

1138

1139 **Figure. 6**





1175 **Fig. 6 MHB glutamatergic/cholinergic neurons participate in generalization formation and**

1176 **extinction of visual aversion. a** Schematic diagram depicting virus and drug injections for activation

1177 of MS→MHB cholinergic circuits and inhibition of MHB glutamatergic neurons with chemogenetic

1178 approaches. **b** Representative image of expressions of AAVs (used in **a**) in the MHB. **c, d** Data of visual

1179 aversion generalization task in mice whose MS→MHB cholinergic circuits were activated while MHB

1180 glutamatergic neurons were inhibited with chemogenetic manipulations (representative trace of mice,

1181 **c**; quantification of the percentage of time spent in each chamber during generalization formation and

1182 extinction phases, **d**). CNO (3.0 μ M/0.1 μ L/side) was bilaterally injected into the MHB by cannulas 30

1183 min before generalization formation test. $n = 10$. **e** Representative image (**e**, top) and quantification (**e**,

1184 bottom) of co-localization of CaMKII α (red) with ChAT (green) in MHB neurons by

1185 immunohistochemistry. $n = 5$, four sections per mouse. **f** Schematic diagram depicting virus and drug

1186 injections for chemogenetic inhibition of MS→MHB cholinergic circuits and activation of MHB

1187 glutamatergic/cholinergic neurons with chemogenetic approaches. **g** Representative image of

1188 expressions of AAVs (used in **f**) in the MHB. **h, i** Data of visual aversion generalization task in mice

1189 whose MS→MHb cholinergic circuits were inhibited while MHb glutamatergic/cholinergic neurons
1190 were activated with chemogenetic manipulations (representative trace of mice, **h**; quantification of the
1191 percentage of time spent in each chamber during generalization formation and extinction phases, **i**).
1192 CNO (3.0 μ M/0.1 μ L/side) was bilaterally injected into the MHb by cannulas 30 min before
1193 generalization formation test. $n = 10$. Scale bar, 50 μ m (**b**, **e** and **g**). Data are mean \pm s.e.m. $*P < 0.05$,
1194 $***P < 0.001$, n.s.: $P > 0.05$ (one-way ANOVA with Tukey's post-hoc analysis for **d** and **i**). Exact p
1195 values and additional statistical information can be found in Supplementary Table 2.

1196

1197

1198

1199

1200

1201

1202

1203

1204

1205

1206

1207


1208

1209

1210

1211

1212 **Figure. 7**



1225 **Fig. 7 MHb glutamatergic/cholinergic neurons mediate regulatory effects of MS→MHb**

1226 **cholinergic circuit via M1 mAChRs. a** Schematic diagram depicting virus injections for whole-cell

1227 recording of EPSC in MHb neurons. **b** Representative image of AAVs expression in the MHb three

1228 weeks after AAV-ChR2 injection. MHb glutamatergic/cholinergic neurons (MHb^{CaMKII α +ChAT⁺}) were

1229 labeled with chat-EGFP and CaMKII α -mCherry. MHb glutamatergic neurons without releasing

1230 acetylcholine (MHb^{CaMKII α +ChAT⁻}) were labeled with CaMKII α -mCherry alone. Scale bar, 50 μ m. **c**

1231 Representative traces of EPSCs in MHb^{CaMKII α +ChAT⁺} and MHb^{CaMKII α +ChAT⁻} neurons. EPSCs were

1232 recorded at -70 mV. Optogenetic stimulations (465 nm, 5 ms, 20 Hz) of ChR2⁺ axonal terminals and

1233 M1 mAChRs blockade were performed during the recording of EPSCs. **d, e** Quantification of

1234 frequency (**m**) and amplitude (**n**) of EPSCs. $n = 12$ cells from four mice. Data are mean \pm s.e.m. * $P <$

1235 0.05, ** $P < 0.01$, *** $P < 0.001$, n.s.: $P > 0.05$ (one-way ANOVA with Tukey's post-hoc analysis for **m**
1236 and **n**). Exact p values and additional statistical information can be found in Supplementary Table 2.

1237

1238

1239

1240

1241

1242

1243

1244

1245

1246

1247

1248

1249

1250

1251

1252

1253


1254

1255

1256

1257

1258 **Figure. 8**



1268 **Fig. 8 Conceptual diagrams for generalization formation and extinction of visual aversion**

1269 **mediated by MS→MHb cholinergic circuits.** A model for visual aversion generalization formation

1270 and extinction is built whereby highly similarity between dynamic stripe image (aversive image) and

1271 static stripe image (neutral image). Activation of the MS→MHb cholinergic circuit drives

1272 generalization formation while its silence supports subsequent extinction. Moreover, MS→MHb

1273 cholinergic projections modulate generalization formation and extinction of visual aversion via M1

1274 mAChRs on downstream glutamatergic/cholinergic neurons.

Figures




Figure 1

MS provides strong cholinergic projections to the MHb. a Schematic diagram of virus injection of AAV-chat-cre-EGFP into the MS to track its cholinergic projections. b Representative images of AAV-chat-cre-EGFP expression in the MS three weeks after virus injection. The numbers correspond to anterior-posterior

distance (in mm) from bregma. c Representative image of EGFP-labeled cholinergic neurons (green) stained with anti-ChAT (red) in the MS by immunohistochemistry. Inset, magnification of targeted neuron marked with a white arrow. d Quantification of the percentage of ChAT+ EGFP+ cells (blue) relative to all EGFP-labeled cholinergic neurons in the MS. Quantification of the percentage of ChAT+ EGFP+ cells (red) relative to all anti-ChAT neurons in the MS. n = 5, four sections per mouse. e Representative image of EGFP-labeled MS cholinergic neurons in whole-cell patch-clamp recording after a 6-8 weeks expression of AAV-chat-cre-EGFP. f Response of EGFP-labeled MS cholinergic neurons to intracellular current steps during whole-cell recording. Depolarizing current: +80 pA; hyperpolarization current: -80 pA. g Representative whole-brain mapping of EGFP-labeled cholinergic projections from the MS to the MHb. Scale bar, 400 μ m (b), 100 μ m (c), 50 μ m (e), 400 μ m (g, middle) and 50 μ m (g, right). Data are mean \pm s.e.m. Additional statistical information can be found in Supplementary Table 2.




Figure 2

MS cholinergic neuron supports rapid generalization formation and extinction of visual aversion in mice. a Scheme of a visual aversion task based on real-time place preference (RTPP) caused by vision. Red arrows show movement direction of the dynamic stripe image. b Representative trace of the locomotion in visual aversion task in mice. c Quantification of the percentage of time spent (c, left) or distance moved (c, right) in each chamber during test phase. n = 15. d Scheme of a generalization task with visual aversion stimulus during training phase. e, f Representative movement trace and quantification of the percentage of time spent in each chamber in test phase 1 and 2 (test phase 1: generalization formation phase of visual aversion, e; test phase 2: generalization extinction phase, f). n = 50. g Scheme of a generalization task without visual aversion stimulus during training phase. h, i Representative movement trace and quantification of the percentage of time spent (by mice without suffering aversion stimulus) in each chamber in test phase 1 and 2. n = 30. j Representative images of ChAT and c-Fos immunostaining in MS neurons of mice subjected to aversion generalization task. k Quantification of c-Fos+ ChAT+

neurons in the MS. n = 5, four sections per mouse. l Schematic diagram of virus injections and optic fiber implantation for recording of GCaMP6m fluorescence signals of MS cholinergic neurons. m Representative images of GCaMP6m expression in the MS. n Schematic diagram of the fiber photometry setup. Ca²⁺ transients were recorded from GCaMP6m-expressing MS cholinergic neurons in mice subjected to visual aversion generalization task. o, p Upper panel: the heatmap illustration of Ca²⁺ signals aligned to the onset of aversion generalization formation or extinction assessment. Each row represents one bout. Lower panel: the peri-event plot of the average AAV Ca²⁺ signal transients. 0 s means time from mice first entering the chamber with stripe images onset. n = 10. Thick red lines indicate mean and shaded areas indicate SEM. Mice with aversion stimulus (o), mice without aversion stimulus (p). Scale bar, 200 μ m (j), 400 μ m (m, top) and 50 μ m (m, bottom). Data are mean \pm s.e.m. **P < 0.01, ***P < 0.001 (two-tailed unpaired Student's t test for c, e, f, h and i; one-way ANOVA with Tukey's post-hoc analysis for k). Exact p values and additional statistical information can be found in Supplementary Table 2.




Figure 3

MS cholinergic neuron activity is necessary for generalization formation and extinction of visual aversion. a Schematic diagram depicting virus injections for apoptosis of MS cholinergic neurons. b, c Representative images (b) and quantification (c) of EGFP-labeled MS cholinergic neurons in taCaspase3-

expressing or control mice. n = 5, four sections per mouse. d, e Data of visual aversion generalization task in mice whose MS cholinergic neurons were inhibited with apoptosis manipulation (representative trace of mice, d; quantification of the percentage of time spent in each chamber during generalization formation and extinction phases, e). n = 15. f Scheme of visual aversion generalization task with optogenetic inhibition approach using a yellow-light (589 nm, 10 mW). g Schematic diagram depicting virus injections for optogenetic inhibition of MS cholinergic neurons. h Yellow light decreased spontaneous firing in MS cholinergic neurons expressing NpHR-mCherry in brain slices. n = 12 cells from four mice. i, j Data of visual aversion generalization task in mice whose MS cholinergic neurons were inhibited with optogenetic manipulation (representative trace of mice, i; quantification of the percentage of time spent in each chamber during generalization phases, j). n = 15. k Schematic diagram depicting virus injections for chemogenetic activation of MS cholinergic neurons. Bath application of CNO (5 μ M) increased spontaneous firing in MS cholinergic neurons expressing hM3Dq-mCherry in brain slices. n = 12 cells from four mice. m, n Data of visual aversion generalization task in mice whose MS cholinergic neurons were activated with chemogenetic manipulation (representative trace of mice, m; quantification of the percentage of time spent in each chamber during generalization phases, n). Mice were intraperitoneally injected with CNO (2.5 mg/kg) after generalization formation test. n = 15. Scale bar, 200 μ m (b). Data are mean \pm s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, n.s.: p > 0.05 (two-tailed unpaired Student's t test for c, h and l; one-way ANOVA with Tukey's post-hoc analysis for e, j and n). Exact p values and additional statistical information can be found in Supplementary Table 2.




Figure 4

MS-MHb cholinergic circuit drives generalization formation and extinction of visual aversion. a Schematic diagram depicting virus injections for chemogenetic inhibition of MS-MHb cholinergic circuits. b Representative image of AAVs expression in the MHb three weeks after AAV-hM4D(Gi) injection. c, d Data of visual aversion generalization task in mice whose MS-MHb cholinergic circuits were inhibited with chemogenetic manipulation (representative trace of mice, c; quantification of the percentage of time spent in each chamber during generalization formation and extinction phases, d). Mice were

intraperitoneally injected with CNO (2.5 mg/kg) 30 min before generalization formation test. n = 15. e Scheme of visual aversion generalization task with an optogenetic activation approach using blue-light pulse (465 nm, 20 Hz, 40 ms). f Schematic diagram depicting virus injections for optogenetic activation of MS→MHb cholinergic circuits. g Representative image of AAVs expression in the MHb three weeks after AAV-ChR2 injection. h, i Data of visual aversion generalization task in mice whose MS→MHb cholinergic circuits were activation with optogenetic manipulation (representative trace of mice, h; quantification of the percentage of time spent in each chamber during generalization formation and extinction phases, i). Scale bar, 100 μm (b and g). Data are mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, n.s.: p > 0.05 (one-way ANOVA with Tukey's post-hoc analysis for d and i). Exact p values and additional statistical information can be found in Supplementary Table 2.




Figure 5

M1 mAChRs and glutamatergic neurons in the MHb are involved in generalization formation and extinction of visual aversion. **a** Schematic diagram depicting virus and drug injections for chemogenetic activation of MS→MHb cholinergic circuits and blockade of MHb M1 mAChRs. **b** Representative image of AAVs expression in the MHb three weeks after AAV-hM3D(Gq) injection. **c, d** Data of visual aversion generalization task in mice whose MS→MHb cholinergic circuits were activated with chemogenetic manipulation while MHb M1 mAChRs were blocked by pirenzepine (representative trace of mice, **c**;

quantification of the percentage of time spent in each chamber during generalization formation and extinction phases, d). Mice were injected with CNO (3.0 μ M/0.1 μ L/side) or CNO + Pirenzepine (1.5 μ g/0.1 μ L/side) into the MHb by cannulas 30 min before generalization formation test. n = 10. e Schematic diagram of virus injections and optic fiber implantation for recording of acetylcholine fluorescence signals of MHb glutamatergic neurons. f Representative images of ACh2.0 expression in the MHb three weeks after AAV-ACh2.0 injection. g Acetylcholine transmissions in MHb glutamatergic neurons were involved in generalization formation (g, left) and extinction (g, right) of visual aversion. Upper panel, the heatmap illustration of acetylcholine signals aligned to the onset of individual generalization assessments. Each row represents one bout, and a total of 10 bouts are illustrated. Lower panel, the peri-event plot of the average acetylcholine signal transients. 0 s means time from mice first entering the chamber with stripe images onset. n = 10. Thick red lines indicate mean and shaded areas indicate SEM. Scale bar, 100 μ m (b), 200 μ m (f, left) and 50 μ m (f, right). Data are mean \pm s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, n.s.: p > 0.05 (one-way ANOVA with Tukey's post-hoc analysis for d). Exact p values and additional statistical information can be found in Supplementary Table 2.

with chemogenetic manipulations (representative trace of mice, c; quantification of the percentage of time spent in each chamber during generalization formation and extinction phases, d). CNO (3.0 $\mu\text{M}/0.1 \mu\text{L}/\text{side}$) was bilaterally injected into the MHb by cannulas 30 min before generalization formation test. $n = 10$. e Representative image (e, top) and quantification (e, bottom) of co-localization of CaMKII α (red) with ChAT (green) in MHb neurons by immunohistochemistry. $n = 5$, four sections per mouse. f Schematic diagram depicting virus and drug injections for chemogenetic inhibition of MS-MHb cholinergic circuits and activation of MHb glutamatergic/cholinergic neurons with chemogenetic approaches. g Representative image of expressions of AAVs (used in f) in the MHb. h, i Data of visual aversion generalization task in mice whose MS-MHb cholinergic circuits were inhibited while MHb glutamatergic/cholinergic neurons were activated with chemogenetic manipulations (representative trace of mice, h; quantification of the percentage of time spent in each chamber during generalization formation and extinction phases, i). CNO (3.0 $\mu\text{M}/0.1 \mu\text{L}/\text{side}$) was bilaterally injected into the MHb by cannulas 30 min before generalization formation test. $n = 10$. Scale bar, 50 μm (b, e and g). Data are mean \pm s.e.m. * $P < 0.05$, *** $P < 0.001$, n.s.: $P > 0.05$ (one-way ANOVA with Tukey's post-hoc analysis for d and i). Exact p values and additional statistical information can be found in Supplementary Table 2.




Figure 7

MHb glutamatergic/cholinergic neurons mediate regulatory effects of MS-MHb cholinergic circuit via M1 mAChRs. a Schematic diagram depicting virus injections for whole-cell recording of EPSC in MHb neurons. b Representative image of AAVs expression in the MHb three weeks after AAV-ChR2 injection. MHb glutamatergic/cholinergic neurons (MHbCaMKII α +ChAT+) were labeled with chat-EGFP and CaMKII α -mCherry. MHb glutamatergic neurons without releasing acetylcholine (MHbCaMKII α +ChAT-) were labeled with CaMKII α -mCherry alone. Scale bar, 50 μ m. c Representative traces of EPSCs in MHbCaMKII α +ChAT+ and MHbCaMKII α +ChAT- neurons. EPSCs were recorded at -70 mV. Optogenetic stimulations (465 nm, 5 ms, 20 Hz) of ChR2+ axonal terminals and M1 mAChRs blockade were performed during the recording of EPSCs. d, e Quantification of frequency (m) and amplitude (n) of EPSCs. n = 12 cells from four mice. Data are mean \pm s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, n.s.: P > 0.05 (one-way ANOVA with Tukey's post-hoc analysis for m and n). Exact p values and additional statistical information can be found in Supplementary Table 2.




Figure 8

Conceptual diagrams for generalization formation and extinction of visual aversion mediated by MS-MHb cholinergic circuits. A model for visual aversion generalization formation and extinction is built whereby highly similarity between dynamic stripe image (aversive image) and static stripe image (neutral image). Activation of the MS-MHb cholinergic circuit drives generalization formation while its silence supports subsequent extinction. Moreover, MS-MHb cholinergic projections modulate generalization formation and extinction of visual aversion via M1 mAChRs on downstream glutamatergic/cholinergic neurons.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [SupplementaryTable1.xlsx](#)
- [SupplementaryTable2.xlsx](#)
- [Supplementaryinformation.pdf](#)